Noah Hahn

Associate Professor - Par

20052018
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 2 Similar Profiles
Urinary Bladder Neoplasms Medicine & Life Sciences
Carcinoma Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Cisplatin Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Prostatic Neoplasms Medicine & Life Sciences
Muscles Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2005 2018

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)

Rosenberg, J. E. , Hahn, N. M. , Regan, M. M. , Werner, L. , Alva, A. , George, S. , Picus, J. , Alter, R. , Balar, A. , Hoffman-Censits, J. , Grivas, P. , Lauer, R. , Guancial, E. A. , Hoimes, C. , Sonpavde, G. , Albany, C. , Stein, M. N. , Breen, T. , Jacobs, C. , Anderson, K. & 4 others Bellmunt, J., Lalani, A. K. A., Pal, S. & Choueiri, T. K. May 16 2018 (Accepted/In press) In : British Journal of Cancer. p. 1-8 8 p.

Research output: Contribution to journalArticle

docetaxel
Platinum
Carcinoma
Survival
Disease-Free Survival

Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method

Chalfin, H. J., Kates, M., van der Toom, E. E., Glavaris, S., Verdone, J. E., Hahn, N. M., Pienta, K. J., Bivalacqua, T. J. & Gorin, M. A. Jan 1 2018 (Accepted/In press) In : Urology.

Research output: Contribution to journalArticle

Circulating Neoplastic Cells
Urinary Bladder Neoplasms
Neoplasms
Carcinoma
Muscles

Commentary on “Prognostic effect of carcinoma in situ in muscle-invasive urothelial carcinoma patients receiving neoadjuvant chemotherapy.”

Thomas, D. E. , Kaimakliotis, H. Z. , Rice, K. R. , Pereira, J. A. , Johnston, P. , Moore, M. L. , Reed, A. , Cregar, D. M. , Franklin, C. , Loman, R. L. , Koch, M. O. , Bihrle, R. , Foster, R. S. , Masterson, T. A. , Gardner, T. A. , Sundaram, C. P. , Powell, C. R. , Beck, S. D. W. , Grignon, D. J. , Cheng, L. & 2 others Albany, C. & Hahn, N. M. Jan 1 2018 (Accepted/In press) In : Urologic Oncology: Seminars and Original Investigations.

Research output: Contribution to journalArticle

Carcinoma in Situ
Carcinoma
Drug Therapy
Muscles
Urinary Bladder Neoplasms
Carcinoma
Drug Therapy
Control Groups
Biopsy
Education

Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel

Harshman, L. C., Chen, Y. H., Liu, G., Carducci, M. A., Jarrard, D., Dreicer, R., Hahn, N., Garcia, J. A., Hussain, M., Shevrin, D., Eisenberger, M., Kohli, M., Plimack, E. R., Cooney, M., Vogelzang, N. J., Picus, J., Dipaola, R. & Sweeney, C. J. Feb 1 2018 In : Journal of Clinical Oncology. 36, 4, p. 376-382 7 p.

Research output: Contribution to journalArticle

docetaxel
Prostate-Specific Antigen
Androgens
Prostatic Neoplasms
Hormones